Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.
Zeke Faux is the author of Number Go Up: Inside Crypto's Wild Rise and Staggering Fall. Motley Fool host Mary Long caught up with Faux for a conversation about: The most genuine argument for crypto ...